Trials / Completed
CompletedNCT05414175
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
A Phase 3, Open-label, Single Arm, Clinical Study to Evaluate Efficacy, Safety and Tolerability of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | Specified dose on specified days |
Timeline
- Start date
- 2022-08-19
- Primary completion
- 2023-11-27
- Completion
- 2025-12-11
- First posted
- 2022-06-10
- Last updated
- 2026-01-27
- Results posted
- 2024-12-04
Locations
20 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05414175. Inclusion in this directory is not an endorsement.